Based on the DexCom Inc stock forecast from 15 analysts, the average analyst target price for DexCom Inc is USD 104.77 over the next 12 months. DexCom Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of DexCom Inc is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, DexCom Inc’s stock price was USD 74.46. DexCom Inc’s stock price has changed by -0.29% over the past week, +2.55% over the past month and -31.66% over the last year.
No recent analyst target price found for DexCom Inc
No recent average analyst rating found for DexCom Inc
Company Overview DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. Read Less
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healt...Read More
Frequently Asked Questions About DexCom Inc (DXCM) Stock
Based on ratings from 15 analysts DexCom Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 16 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on DXCM's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for DXCM is USD 104.77 over the next 12 months. The maximum analyst target price is USD 160 while the minimum anlayst target price is USD 75.
DXCM stock's Price/Earning ratio is 42.64.
Our analysis grades DXCM stock's Price / Earning ratio at F. This means that DXCM stock's Price/Earning ratio is above 59.00000000000001% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this DXCM may be a overvalued for its sector.
The last closing price of DXCM's stock was USD 74.46.
The most recent market capitalization for DXCM is USD 27.48B.
Based on targets from 15 analysts, the average taret price for DXCM is projected at USD 104.77 over the next 12 months.
This means that DXCM's stock price may go up by +40.71% over the next 12 months.
We can't find any ETFs which contains DexCom Inc's stock.
As per our most recent records DexCom Inc has 9,500 Employees.
DexCom Inc's registered address is 6340 Sequence Drive, San Diego, CA, United States, 92121.
You can get more information about it from DexCom Inc's website at https://www.dexcom.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About DexCom Inc (DXCM) Stock
Based on ratings from 15 analysts DexCom Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 16 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on DXCM's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for DXCM is USD 104.77 over the next 12 months. The maximum analyst target price is USD 160 while the minimum anlayst target price is USD 75.
DXCM stock's Price/Earning ratio is 42.64.
Our analysis grades DXCM stock's Price / Earning ratio at F. This means that DXCM stock's Price/Earning ratio is above 59.00000000000001% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this DXCM may be a overvalued for its sector.
The last closing price of DXCM's stock was USD 74.46.
The most recent market capitalization for DXCM is USD 27.48B.
Based on targets from 15 analysts, the average taret price for DXCM is projected at USD 104.77 over the next 12 months.
This means that DXCM's stock price may go up by +40.71% over the next 12 months.
We can't find any ETFs which contains DexCom Inc's stock.
As per our most recent records DexCom Inc has 9,500 Employees.
DexCom Inc's registered address is 6340 Sequence Drive, San Diego, CA, United States, 92121.
You can get more information about it from DexCom Inc's website at https://www.dexcom.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DXCM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
